Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,703 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,703 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06229392 | A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With… | Phase 1 | withdrawn | Jan 29, 2024 | Rush University Medical Center | Internal operational issues prevented the study site from opening to enrollment. | Enrollment / accrual |
| NCT04166383 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | Phase 2 | terminated | Nov 18, 2019 | National Cancer Institute (NCI) | Interim analysis indicated limited efficacy | Efficacy / futility |
| NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With…(CELLO-1) | Phase 1 / Phase 2 | terminated | Nov 27, 2019 | Epizyme, Inc. | The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in… | Safety / toxicity |
| NCT03868475 | Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline…(VAPEX) | N/A | withdrawn | Mar 11, 2019 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Publication of only protocol desired | Other (stated, no rule matched) |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | Phase 3 | terminated | Mar 2, 2021 | Translational Research in Oncology | The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve… | Enrollment / accrual |
| NCT05636267 | Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | Phase 1 / Phase 2 | terminated | Dec 5, 2022 | Akeso | Terminated due to sponsor strategic development reprioritization. | Sponsor / business decision |
| NCT05956795 | Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous… | — | terminated | Jul 21, 2023 | Johns Hopkins University | Expired in IRB | Other (stated, no rule matched) |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With…(MAST) | Phase 1 | terminated | Apr 26, 2022 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT06219174 | Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC… | Phase 1 / Phase 2 | suspended | Jan 23, 2024 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable | Other (stated, no rule matched) |
| NCT06292975 | Exercise for Improving Radiotherapy Efficacy in Rectal Cancer | N/A | withdrawn | Mar 5, 2024 | University of Hull | Although patients were screened, only two met the eligibility criteria within the available… | Enrollment / accrual |
| NCT06860386 | Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC | Phase 2 | suspended | Mar 6, 2025 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced…(AcceleRET-Lung) | Phase 3 | terminated | Jan 10, 2020 | Hoffmann-La Roche | Early termination of the study resulted from organizational and commercial decisions that led to… | Other (stated, no rule matched) |
| NCT04327700 | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | Phase 2 | terminated | Mar 31, 2020 | Wake Forest University Health Sciences | Slow accruals | Enrollment / accrual |
| NCT06114940 | Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma…(PLUTO) | Phase 2 | terminated | Nov 2, 2023 | Jinling Hospital, China | Involving changes to the primary endpoint, it is difficult to unify the evaluation criteria for… | Other (stated, no rule matched) |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT04880382 | Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration…(OPTIMUNELUNG) | Phase 2 | terminated | May 10, 2021 | Institut Bergonié | Enrolment was slowlier than expected. | Enrollment / accrual |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)… | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment | Enrollment / accrual |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the… | Phase 1 / Phase 2 | terminated | Mar 5, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04895748 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in… | Phase 1 | terminated | May 20, 2021 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT05554354 | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in… | Phase 2 | terminated | Sep 26, 2022 | National Cancer Institute (NCI) | Other - slow accrual | Enrollment / accrual |
| NCT05676463 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | Phase 2 | terminated | Jan 9, 2023 | Thomas Jefferson University | Loss of required MRI resources needed to conduct protocol-specified procedures | Other (stated, no rule matched) |
| NCT06315296 | An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing… | N/A | terminated | Mar 18, 2024 | Thomas Jefferson University | slow accrual | Enrollment / accrual |
| NCT05296135 | Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer(PREDAPT-HNSCC2) | — | withdrawn | Mar 25, 2022 | Cofactor Genomics, Inc. | No patients were recruited or enrolled in this study. | Enrollment / accrual |
| NCT03801369 | AMTEC IIT: Phase 2 Multiarm Study in TNBC | Phase 2 | terminated | Jan 11, 2019 | Gordon Mills, MD, PhD | loss of funding | Funding |
| NCT05159050 | Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis | Phase 1 | terminated | Dec 15, 2021 | Carlos Chan | Drug supply issues | Drug supply |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With… | Phase 1 | terminated | Apr 20, 2016 | Regeneron Pharmaceuticals | Due to a Dose Limiting Toxicity. | Safety / toxicity |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary… | Phase 2 | terminated | Dec 24, 2018 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | Phase 1 / Phase 2 | withdrawn | Oct 4, 2022 | Intima Bioscience, Inc. | No recruitment | Enrollment / accrual |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT03066206 | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Phase 2 | terminated | Feb 28, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03366766 | Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable… | Phase 2 | terminated | Dec 8, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | slow accrual and lack of additional funding | Enrollment / accrual |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic… | Phase 1 | terminated | Feb 10, 2022 | Pfizer | Study terminated based on internal business considerations and was not based on safety reasons | Safety / toxicity |
| NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Phase 1 | terminated | Oct 13, 2022 | Mirati Therapeutics Inc. | business objectives have changed | Sponsor / business decision |
| NCT03165721 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in… | Phase 2 | terminated | May 24, 2017 | National Cancer Institute (NCI) | Study closed to enrollment due to low accrual. | Enrollment / accrual |
| NCT06217094 | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 | withdrawn | Jan 22, 2024 | University of Florida | funding terminated | Funding |
| NCT06851104 | A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With… | Phase 2 | terminated | Feb 28, 2025 | Guangxi Medical University | The support from the relevant company was not obtained as planned | Sponsor / business decision |
| NCT02738606 | Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver… | Phase 2 | terminated | Apr 14, 2016 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With… | Phase 1 / Phase 2 | withdrawn | Apr 5, 2022 | Institut de Recherches Internationales Servier | Strategic development reasons | Sponsor / business decision |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT06010355 | Culturally Tailored Educational Video to Promote Lung Cancer Screening in Vulnerable… | N/A | terminated | Aug 24, 2023 | Thomas Jefferson University | Trial is terminated due to lack of staffing | Other (stated, no rule matched) |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination… | Phase 1 / Phase 2 | terminated | Apr 5, 2017 | M.D. Anderson Cancer Center | \<75% accrued | Enrollment / accrual |
| NCT03559049 | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small… | Phase 1 / Phase 2 | terminated | Jun 15, 2018 | University of Michigan Rogel Cancer Center | Due to financial hardships suffered by the stakeholder | Funding |
| NCT06585969 | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal…(DISCORDANT) | Phase 3 | withdrawn | Sep 19, 2024 | Danish Breast Cancer Cooperative Group | Lack of funding | Funding |
| NCT05360745 | Quality of Life With Nutritional Supplementation in Patients With Locally…(FOODPANC) | N/A | withdrawn | May 4, 2022 | Fundacion para la Excelencia y la Calidad de la Oncologia | Few months later the site initiation visit, the principal investigator decided not to continue with… | Investigator |
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial(ARCITECT) | Phase 2 | suspended | Jul 3, 2023 | Michael B. Atkins, MD | Interim Analysis | Efficacy / futility |
| NCT03875144 | Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)(MESOTIP) | Phase 2 | suspended | Mar 14, 2019 | Institut du Cancer de Montpellier - Val d'Aurelle | This decision was taken following the occurrence of three cases of serious and unexpected suspected… | Safety / toxicity |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT06716853 | A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With…(TEM-GU) | Phase 1 / Phase 2 | terminated | Dec 4, 2024 | Genenta Science | Persistent challenges have been encountered in patient recruitment, difficulty in identifying a… | Safety / toxicity |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Mar 11, 2026source: clinicaltrials